drugset / Trial / NCT03461627
Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
assess the efficacy and safety of Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) in combination with seretide to patients with Asthma. a randomized, double-blind, double-dummy, positive-controlled, parallel-group trail.
Timeline
- Start
- 2017-04-01
- Primary completion
- 2018-10-31
- Completion
- 2018-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone | Other / unclassified | 250 ug | Inhaled |
| Comparator | Fluticasone propionate | Other / unclassified | 50 ug | — |
| Comparator | Fluticasone propionate | Other / unclassified | 250 ug | — |
| Subject | Salmeterol | Other / unclassified | 50 ug | Inhaled |